Medincell SA Net Assets

Latest as of March 2026: €3.06 Million EUR ≈ $3.58 Million USD

Medincell SA net assets. Based on the latest financial reports, Medincell SA (MEDCL) has net assets worth €3.06 Million EUR (≈ $3.58 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€108.05 Million ≈ $126.33 Million USD) and total liabilities (€104.99 Million ≈ $122.74 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Medincell SA net asset momentum to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€3.06 Million
% of Total Assets	2.84%
Annual Growth Rate	8.75%
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	45.39

Net Assets of Medincell SA (2016–2026)

Net assets of Medincell SA from 2016 to 2026. This chart illustrates how Medincell SA's net assets have evolved over time, based on quarterly financial data. See Medincell SA net asset quality index to measure how much of total assets are equity-financed.

Annual Net Assets for Medincell SA (2016–2026)

The table below shows the annual net assets of Medincell SA from 2016 to 2026. For live market cap and overall valuation, see how much is Medincell SA worth.

Year	Net Assets	Change
2026-03-31	€3.06 Million ≈ $3.58 Million	+118.72%
2025-03-31	€-16.37 Million ≈ $-19.13 Million	+59.91%
2024-03-31	€-40.82 Million ≈ $-47.73 Million	+3.48%
2023-03-31	€-42.29 Million ≈ $-49.45 Million	-216.31%
2022-03-31	€-13.37 Million ≈ $-15.63 Million	-249.97%
2021-03-31	€8.92 Million ≈ $10.42 Million	+155.87%
2020-03-31	€-15.96 Million ≈ $-18.66 Million	-355.61%
2019-03-31	€6.24 Million ≈ $7.30 Million	+153.14%
2018-03-31	€-11.75 Million ≈ $-13.74 Million	-413.51%
2017-03-31	€-2.29 Million ≈ $-2.67 Million	-272.81%
2016-03-31	€1.32 Million ≈ $1.55 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Medincell SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 5130.1% over the analyzed period, potentially due to dividend distributions or operating losses.

Medincell SA Net Assets Breakdown (March 2026)

Medincell SA net assets breakdown by equity component as of March 2026.

Component	Amount	Percentage
Common Stock	€359.00K	11.72%
Other Comprehensive Income	€-11.45 Million	-373.56%
Other Components	€45.44 Million	1482.96%
Total Equity	€3.06 Million	100.00%

Medincell SA Competitors by Market Cap

The table below lists competitors of Medincell SA ranked by their market capitalization.

Company	Market Cap
Vesuvius India Limited NSE:VESUVIUS	$790.95 Million
Kornit Digital Ltd NASDAQ:KRNT	$791.50 Million
Raymond Limited NSE:RAYMOND	$791.85 Million
Elco Ltd TA:ELCO	$791.89 Million
Tourism Finance Corporation of India Limited NSE:TFCILTD	$790.69 Million
Apogee Enterprises Inc NASDAQ:APOG	$790.49 Million
Heartland Express Inc NASDAQ:HTLD	$790.34 Million
Asseco Business Solutions S.A. WAR:ABS	$790.18 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Medincell SA's equity between the two most recent reporting periods.

Equity Growth Insights

From 2025 to 2026, total equity changed from -16,367,000 to 3,064,000, a change of 19,431,000.
Net loss of 31,287,000 reduced equity.
New share issuances of 45,510,000 increased equity.
Other comprehensive income increased equity by 75,977,000.
Other factors decreased equity by 70,769,000.

Equity Change Factors (2025 to 2026)

Factor	Impact	Contribution
Net Income	€-31.29 Million	-1021.12%
Share Issuances	€45.51 Million	+1485.31%
Other Comprehensive Income	€75.98 Million	+2479.67%
Other Changes	€-70.77 Million	-2309.69%
Total Change	€-	%

Book Value vs Market Value Analysis

This analysis compares Medincell SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 308.92x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 307.53x to 308.92x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-03-31	€0.09	€26.36	x
2017-03-31	€-0.16	€26.36	x
2018-03-31	€-0.82	€26.36	x
2019-03-31	€0.36	€26.36	x
2020-03-31	€-0.79	€26.36	x
2021-03-31	€0.40	€26.36	x
2022-03-31	€-0.54	€26.36	x
2023-03-31	€-1.68	€26.36	x
2024-03-31	€-1.44	€26.36	x
2025-03-31	€-0.56	€26.36	x
2026-03-31	€0.09	€26.36	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Medincell SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -1021.12%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -160.27%
• Asset Turnover: 0.18x
• Equity Multiplier: 35.27x
Recent ROE (-1021.12%) is below the historical average (-136.33%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	50.16%	7.56%	0.74x	9.01x	€498.00K
2017	0.00%	-41.73%	0.37x	0.00x	€-3.33 Million
2018	0.00%	-148.66%	0.25x	0.00x	€-8.39 Million
2019	-315.35%	-1364.31%	0.04x	6.08x	€-20.31 Million
2020	0.00%	-838.53%	0.10x	0.00x	€-22.32 Million
2021	-213.32%	-232.35%	0.13x	7.13x	€-19.91 Million
2022	0.00%	-606.50%	0.09x	0.00x	€-23.47 Million
2023	0.00%	-321.90%	0.34x	0.00x	€-27.78 Million
2024	0.00%	-273.34%	0.25x	0.00x	€-20.96 Million
2025	0.00%	-72.19%	0.28x	0.00x	€-16.80 Million
2026	-1021.12%	-160.27%	0.18x	35.27x	€-31.59 Million

Industry Comparison

This section compares Medincell SA's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $1,337,853
Average return on equity (ROE) among peers: -92.72%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Medincell SA (MEDCL)	€3.06 Million	50.16%	34.27x	$790.73 Million
Abionyx Pharma SA (ABNX)	$7.92 Million	-44.41%	0.87x	$66.65 Million
Abivax SA (ABVX)	$4.67 Million	-803.57%	14.26x	$8.06 Billion
Adocia (ADOC)	$-12.97 Million	0.00%	0.00x	$69.26 Million
Aelis Farma SA (AELIS)	$10.12 Million	-73.71%	0.95x	$11.52 Million
Biophytis S.A. (ALBPS)	$-409.32K	0.00%	0.00x	$1.52 Million
Cellectis (ALCLS)	$6.40 Million	0.00%	0.20x	$88.25 Million
Advicenne (ALDVI)	$-19.07 Million	0.00%	0.00x	$11.01 Million
Genoway (ALGEN)	$17.38 Million	9.02%	0.83x	$29.86 Million
Integragen (ALINT)	$1.76 Million	-14.58%	2.14x	$579.30K
Medesis Pharma SA (ALMDP)	$-2.42 Million	0.00%	0.00x	$1.80 Million

About Medincell SA

PA:MEDCL France Biotechnology

Market Cap

$1.11 Billion

€946.58 Million EUR

Market Cap Rank

#9567 Global

#152 in France

Share Price

€26.36

Change (1 day)

+0.38%

52-Week Range

€20.24 - €37.62

All Time High

€38.46